Form 8-K - Current report:
SEC Accession No. 0001193125-24-223292
Filing Date
2024-09-23
Accepted
2024-09-23 08:18:52
Documents
15
Period of Report
2024-09-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d818761d8k.htm   iXBRL 8-K 41113
2 EX-3.1 d818761dex31.htm EX-3.1 68433
3 EX-10.1 d818761dex101.htm EX-10.1 247024
  Complete submission text file 0001193125-24-223292.txt   577260

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vtyx-20240923.xsd EX-101.SCH 2844
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtyx-20240923_lab.xml EX-101.LAB 18739
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtyx-20240923_pre.xml EX-101.PRE 11703
17 EXTRACTED XBRL INSTANCE DOCUMENT d818761d8k_htm.xml XML 3849
Mailing Address 12790 EL CAMINO REAL, SUITE 200 SAN DIEGO CA 92130
Business Address 12790 EL CAMINO REAL, SUITE 200 SAN DIEGO CA 92130 (858) 945-2393
Ventyx Biosciences, Inc. (Filer) CIK: 0001851194 (see all company filings)

EIN.: 832996852 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40928 | Film No.: 241314683
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)